9-Aminometil-9,10-dihidroantracen

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
9-Aminometil-9,10-dihidroantracen
(IUPAC) ime
9-Aminometil-9,10-dihidroantracen
Klinički podaci
Identifikatori
CAS broj 22136-76-1
ATC kod nije dodeljen
PubChem[1][2] 10398175
ChemSpider[3] 8573613
ChEMBL[4] CHEMBL47482 YesY
Hemijski podaci
Formula C15H15N 
Mol. masa 209,286 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

AMDA (9-Aminometil-9,10-dihidroantracen) je organsko jedinjenje koji deluje kao potentan i selektivan antagonist za 5-HT2A receptor.[5] On je korišten u studijama kojima je utvrđivan oblik 5-HT2A proteina,[6] i kao osnova za razvoj velike familije derivata sa povećanom potentnošću i selektivnošću.[7][8][9][10][11]

Reference[uredi - уреди | uredi kôd]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. Westkaemper, RB; Runyon, SP; Bondarev, ML; Savage, JE; Roth, BL; Glennon, RA (1999). „9-(Aminomethyl)-9,10-dihydroanthracene is a novel and unlikely 5-HT2A receptor antagonist”. European Journal of Pharmacology 380 (1): R5–7. DOI:10.1016/S0014-2999(99)00525-7. PMID 10513561. 
  6. Runyon, SP; Peddi, S; Savage, JE; Roth, BL; Glennon, RA; Westkaemper, RB (2002). „Geometry-affinity relationships of the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene”. Journal of Medical Chemistry 45 (8): 1656–64. DOI:10.1021/jm010354g. PMID 11931619. 
  7. Peddi, S; Roth, BL; Glennon, RA; Westkaemper, RB (2003). „Spiro9,10-dihydroanthracene-9,3'-pyrrolidine-a structurally unique tetracyclic 5-HT2A receptor antagonist”. European Journal of Pharmacology 482 (1–3): 335–7. DOI:10.1016/j.ejphar.2003.09.059. PMID 14660041. 
  8. Peddi, S; Roth, BL; Glennon, RA; Westkaemper, RB (2004). „Structural determinants for high 5-HT(2A) receptor affinity of spiro9,10-dihydroanthracene-9,3(')-pyrrolidine (SpAMDA)”. Bioorganic & Medicinal Chemistry Letters 14 (9): 2279–83. DOI:10.1016/j.bmcl.2004.02.014. PMID 15081025. 
  9. Dewkar, GK; Peddi, S; Mosier, PD; Roth, BL; Westkaemper, RB (2008). „Methoxy-substituted 9-Aminomethyl-9,10-dihydroanthracene (AMDA) Derivatives Exhibit Differential Binding Affinities at the 5-HT2A Receptor”. Bioorganic & Medicinal Chemistry Letters 18 (19): 5268–71. DOI:10.1016/j.bmcl.2008.08.059. PMC 3082371. PMID 18774714. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3082371/. 
  10. Runyon, SP; Mosier, PD; Roth, BL; Glennon, RA; Westkaemper, RB (2008). „Potential Modes of Interaction of 9-Aminomethyl-9,10-dihydroanthracene (AMDA) Derivatives with the 5-HT2A Receptor: A Ligand Structure-Affinity Relationship, Receptor Mutagenesis and Receptor Modeling Investigation”. Journal of Medical Chemistry 51 (21): 6808–28. DOI:10.1021/jm800771x. PMC 3088499. PMID 18847250. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3088499/. 
  11. Shah JR, Mosier PD, Peddi S, Roth BL, Westkaemper RB (February 2010). „9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites”. Bioorganic & Medicinal Chemistry Letters 20 (3): 935–8. DOI:10.1016/j.bmcl.2009.12.064. PMID 20045641.